医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

enfortumab vedotin-ejfv

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv for First-Line Treatment of Advanced Bladder Cancer pembrolizumab sBLA with KEYTRUDA

2023年12月01日

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: and KEYTRUDA enfortumab vedotin-ejfv EV-302 Trial PADCEV pembrolizumab

2023年09月22日

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer pembrolizumab Seagen with KEYTRUDA

2022年12月20日

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Clinical Trial Investigating PADCEV enfortumab vedotin-ejfv pembrolizumab Seagen with KEYTRUDA

2022年09月12日

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: as First-Line Treatment for Advanced Urothelial Cancer enfortumab vedotin-ejfv pembrolizumab Seagen and Astellas Announce Positive Topline Results For PADCEV with KEYTRUDA

2022年07月26日

Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy PADCEV Seagen and Astellas Announce Initial Results

2022年02月15日

U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer

U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv FDA Grants Regular Approval and Expands Indication for PADCEV for Patients with Locally Advanced or Metastatic Urothelial Cancer

2021年07月10日

Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv from Two Trials of PADCEV in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy Seagen and Astellas Announce Updated Results

2021年05月20日

Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV in Locally Advanced or Metastatic Urothelial Cancer Seagen and Astellas Announce

2021年04月19日

Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: enfortumab vedotin-ejfv FDA for PADCEV in Locally Advanced or Metastatic Urothelial Cancer Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the

2021年02月18日